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Summary
Background Intermittent preventive treatment (IPT) for malaria is used in infants, children, adults, and pregnant 
women. Dihydroartemisinin-piperaquine (DP) is an eﬀ ective, well tolerated artemisinin-based combination therapy. 
The long half-life of piperaquine makes it attractive for IPT. We conducted a systematic review and meta-analysis to 
establish the eﬃ  cacy and safety of repeated treatment with DP.
Methods Following PRISMA guidelines, we searched multiple databases on Sept 1, 2016, with the terms: “human” 
AND “dihydroartemisinin-piperaquine” OR “DHA-PPQ”. Studies were eligible if they were randomised controlled 
trials (RCTs) or prospective cohort studies involving repeat exposures to standard 3-day courses of DP for either 
seasonal malaria chemoprevention, mass drug administration, or treatment of clinical malaria, conducted at any time 
and in any geographic location. Random-eﬀ ects meta-analysis was used to generate pooled incidence rate ratios and 
relative risks, or risk diﬀ erences.
Findings 11 studies were included: two repeat treatment studies (one in children younger than 5 years and one in pregnant 
women), and nine IPT trials (ﬁ ve in children younger than 5 years, one in schoolchildren, one in adults, two in pregnant 
women). Comparator interventions included placebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP), 
SP+amodiaquine, SP+piperaquine, SP+chloroquine, and co-trimoxazole. Of 14 628 participants, 3935 received multiple 
DP courses (2–18). Monthly IPT-DP was associated with an 84% reduction in the incidence of malaria parasitaemia 
measured by microscopy compared with placebo. Monthly IPT-DP was associated with fewer serious adverse events than 
placebo, daily co-trimoxazole, or monthly SP.  Among 56 IPT-DP recipients (26 children, 30 pregnant women) with 
cardiac parameters, all QTc intervals were within normal limits, with no signiﬁ cant increase in QTc prolongation with 
increasing courses of DP.
Interpretation Monthly DP appears well tolerated and eﬀ ective for IPT. Additional data are needed in pregnancy and 
to further explore the cardiac safety with monthly dosing.
Funding Bill & Melinda Gates Foundation and NIH.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Malaria is a major, preventable cause of morbidity, 
mortality and adverse birth outcomes in sub-Saharan 
Africa.1,2 Although malaria mortality has fallen as a 
result of the scale-up of insecticide-treated bed nets and 
artemisinin-based combination therapies (ACTs), 
additional eﬀ orts are needed.3 Inter mittent preventive 
treatment (IPT) of malaria is a strategy for the control of 
malaria in pregnant women (IPTp), infants, children 
(seasonal malaria chemoprevention [SMC]),4 and 
potentially in high-risk subgroups of non-pregnant 
adults and schoolchildren. IPT involves the 
administration of curative doses of antimalarials at 
predeﬁ ned intervals irrespective of malaria infection 
status.
Of the available ACTs, dihydroartemisinin-
piperaquine (DP) is one of the most attractive drugs for 
IPT. It is eﬀ ective, with cure rates of 98% or more 
in non-pregnant and pregnant populations.5–7 The 
long half-life of piperaquine (about 23 days [range 19–28] 
in adults and 14 days [range 10–18] in children)6 provides 
1–2 weeks’ longer post-treatment prophylaxis than 
artemether-lumefantrine (AL, half-life 3–6 days),8 
artesunate-amodiaquine (half-life 6–18 days),9 or 
sulfadoxine-pyrimethamine (SP, half-life 4–11 days),10 
and a similar duration of post-treatment prophylaxis as 
meﬂ oquine (half-life 10·5–14 days).11 It is well tolerated 
compared with other antimalarials: side-eﬀ ects are 
typically limited to minor gastrointestinal adverse 
events, mild headache, and dizziness.12
DP can cause dose-dependent prolongation of the QT 
interval13 and is not recommended in patients with 
congenital long QT syndrome (about one in 
2500 children)14 or who are taking other QT prolonging 
drugs.13 Numerous drugs have been associated with QT 
prolongation, including multiple classes of antibiotics 
(eg, erythromycin,15 quinolones,15 co-trimoxazole16) and 
antimalarials.17 Mild QT prolongation is clinically silent, 
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but extreme prolongation can cause arrhythmias, 
including torsade de pointes, a potentially fatal poly-
morphic ventricular tachycardia occurring in roughly 
one of 10 000 exposures to QT prolonging drugs.18 
Diagnosis of prolonged QT requires electrocardiograms 
(ECG); the normal range diﬀ ers for men and women, as 
well as children and adults. Few studies of DP have 
assessed ECGs.19,20
Administration of DP with food, particularly fat, 
increases the bioavailability, leading to increased drug 
concentrations and a greater degree of QT prolongation, 
which persists for a longer duration.21 Additionally, 
piperaquine concentrations might also be increased 
when co-administered with drugs that are CYP3A4-
inhibitors (eg, some protease inhibitors).13 For these 
reasons, the drug manufacturer recommends obtaining 
ECGs to monitor therapy when clinically indicated. 
However, this is not practical if DP is to be given as IPT 
in resource poor settings and studies assessing the 
cardiotoxicity of DP when provided for case 
management show the risk to be low.22 Furthermore, 
neither DP nor AL displayed an in-vitro signal for a 
signiﬁ cant pro-arrhythmic risk or appear to induce 
potential torsadogenic eﬀ ects.23 However, piperaquine 
is elimin ated slowly and theoretically this risk might be 
increased when repeated doses are given, especially 
when given monthly. We conducted a systematic review 
and meta-analysis to assess the eﬃ  cacy, safety, and 
tolerability of repeated dosing of DP when used for case 
management, IPT, mass drug administration or 
seasonal malaria chemoprevention.
Methods
Search strategy
We did a systematic literature search according to 
PRISMA guidelines24 on Sept 1, 2016, using simple search 
terms “human” AND “dihydroartemisinin-piperaquine” 
OR “DHA-PPQ” (see appendix). Studies were eligible if 
they were randomised controlled trials (RCTs) or 
prospective cohort studies involving repeat exposures to 
standard 3-day courses of DP for either chemo-
prevention (IPT/SMC), mass drug administration, or 
treatment of clinical malaria, conducted at any time and in 
any geographic location. The search was restricted to the 
English language (appendix).
Data management
Two independent reviewers (SK, JG) screened titles, 
abstracts, and full texts and agreed on ﬁ nal study 
eligibility. Reviewers independently extracted data using 
a standardised form and database. If required, additional 
information was obtained from authors.
Quality assessment
The Cochrane Collaboration’s tool was used to assess the 
quality and risk of bias of clinical trials.25 The quality of 
observational studies was assessed using the Newcastle 
Ottawa Scale.26
Research in context
Evidence before this study
Malaria is a major, preventable cause of morbidity, mortality, 
and adverse birth outcomes in sub-Saharan Africa. 
Intermittent preventive treatment (IPT) of malaria, which 
involves curative doses of antimalarials at predeﬁ ned intervals 
irrespective of malaria infection status, is a strategy for the 
control of malaria in pregnant women, infants, and children 
(seasonal malaria chemoprevention [SMC]). 
Dihydroartemisinin-piperaquine (DP) is an eﬀ ective, well 
tolerated antimalarial, and the long half-life of piperaquine 
makes DP an attractive choice for IPT. However, DP is known 
to cause dose-dependent prolongation of the QT interval, and 
limited data exists on whether the risk of QT prolongation is 
increased with repeated dosing. We conducted a systematic 
review and meta-analysis to establish the eﬃ  cacy and safety of 
repeated treatment with 3-day courses of DP.
We searched Medline, Embase, Web of Science, Scopus, CINAHL 
Plus, the Cochrane Library databases, WHO Global Health 
Library, the Malaria in Pregnancy Consortium (MiPc) Library, 
‘grey literature’ databases (unpublished literature including 
ongoing clinical trials, ongoing PhDs, unpublished PhDs, 
aborted research, and any other unconventional unpublished 
literature on the topic), and conference abstracts for articles 
published before Sept 1, 2016 using the terms: “human” AND 
“dihydroartemisinin-piperaquine” OR “DHA-PPQ”, and 
restricting the language to English. There are several reviews on 
the safety and eﬃ  cacy of a single course of DP for treatment 
(ie, case management), and one review of studies of IPT in 
children (now called SMC) (including two using DP or other 
piperaquine combinations) and one of IPT in schoolchildren 
(including one trial using DP).
Added value of this study
To our knowledge, this is the ﬁ rst review and meta-analysis to 
speciﬁ cally assess the safety and eﬃ  cacy with repeated courses 
of DP for case management, IPT, mass drug administration or 
seasonal malaria chemoprevention in all age groups when 
compared with placebo or other antimalarial interventions. 
Monthly DP was more eﬀ ective than most other options for the 
prevention of malaria, and appeared to be well tolerated and 
safe, with less serious adverse events than many comparator 
interventions and no evidence for increased risk of adverse 
cardiac events. Nevertheless, data on cardiotoxicity is still scarce.
Implications of all the available evidence
DP is a valuable potential candidate for use as IPT and could 
greatly reduce malaria morbidity and mortality. Additional 
studies incorporating electrocardiogram measurements are 
needed to conﬁ rm the cardiac safety of repeated monthly dosing. 
See Online for appendix
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Data analysis
Random-eﬀ ects meta-analysis was used to generate 
pooled incidence rate ratios (IRR) and relative risks, or 
risk diﬀ erences when there were zero events in both 
study groups, to compare the eﬀ ect of DP relative with 
other antimalarials or placebo on malaria incidence and 
tolerability; odds ratio (OR) was used for serious 
adverse events (SAEs) because they are rare events. To 
correct for studies reporting no SAEs in either the DP 
or comparison group, a ﬁ xed eﬀ ects model with 
continuity correction of 0·5 was used to generate 
Mantel-Haenzel pooled ORs for each study to be 
informative.26
Heterogeneity was expressed as I² value and 
categorised as low if I² was 0–40%, moderate if I² 
was 30–60%, substantial if I² was 50–90%, and 
considerable if I² was 75–100%.24 Analyses were stratiﬁ ed 
by study type (case management vs IPT/SMC/mass drug 
administration) and geographic location (east Africa, 
west Africa, and Asia). Due to scarcity of data, we could 
not stratify on pregnancy status. The inﬂ uence of study 
quality on results was assessed by sensitivity analyses. 
Publication bias was assessed through funnel plots. 
Two-tailed p-values <0·05 were considered statistically 
signiﬁ cant. 
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Our search identiﬁ ed 898 citations; after title review, 
380 abstracts and 46 full text articles (29 distinct 
studies) were reviewed (ﬁ gure 1). 11 studies were 
eligible: one cohort study in pregnant women (n=5288),30 
one RCT of repeated treatments in children younger 
than 5 years (n=312),20 and nine RCTs with IPT/SMC 
(henceforth referred to as IPT). Of the nine RCTs, ﬁ ve 
were in children younger than 5 years (n=5481),6,31–34 one 
in schoolchildren (n=740),35 one in adult men at 
occupational risk of malaria (n=961),36 and two in 
pregnant women (n=1846;37,38 table). In total, there were 
14 628 participants; 4883 in DP groups, of whom 4511 
were exposed to DP and 3935 received at least 
two courses of DP, including 762 pregnant women and 
1913 children aged less than 5 years. The remaining 
9745 were exposed to placebo or other comparator 
therapy (including 990 exposed to SP–piperaquine). 
The 4511 participants exposed to DP received a total of 
18 873 courses, with 18 297 courses taken by the 3935 
participants who received at least two doses, some of 
whom received as many as 18 monthly doses. Several 
diﬀ erent dosing intervals were studied, including 
monthly (including in pregnancy), every 2 months, 
quarterly, and three times during the second and third 
trimester of pregnancy. Comparator interventions 
included placebo, AL, SP, SP+amodiaquine, SP + piper-
aquine, SP + chloroquine, and piper aquine + co-
trimoxazole. All studies were conducted in areas with 
no or low parasite resistance to piperaquine or the 
artemisinins.
The Cochrane Collaboration tool scored four RCTs as 
low risk of bias and six as moderate risk of bias (appendix). 
The Newcastle Ottawa Scale suggested a moderate risk of 
bias for the single cohort study.
Protective eﬃ  cacy
Repeated ﬁ rst-line course of DP for case management 
was associated with a 16% lower risk of parasitological 
treatment failure by day 28 compared with AL, but only 
one trial provided data for analysis (IRR 0·84 95% CI 
0·81–0·86).20
Monthly DP for IPT was associated with an 84% 
reduction in the incidence of malaria parasitaemia 
measured by microscopy compared with placebo 
Figure 1: PRISMA ﬂ ow chart
DP=dihydroartemisinin-piperaquine. AL=artemether-lumefantrine. A second trial29 
reporting on the use of DP for rescue treatment among pregnant women included 
nine women who received at least two courses of DP (six received three courses 
and three received two courses), but all women had also received a preceding 
course of either quinine or intravenous artesunate with or without clindamycin, 
and there were no control women who had not received DP. *One trial28 comparing 
seasonal malaria chemoprevention (SMC) with sulphadoxine-pyrimethamine plus 
amodiaquine vs placebo SMC (passive case detection and case management with 
either DP or AL during the malaria transmissions season) was excluded because 
only 27 of 800 children (3·4%) in placebo SMC group (ie, the DP case management 
group) received two or more courses of DP and safety data by number of courses 
received were not available.
518 records excluded after title review
1324 records identiﬁed through database search
898 records after duplicates removed
380 abstracts screened
46 full-text articles assessed for eligibility
11 studies included in ﬁnal synthesis
334 records excluded after abstract review
35 full-text articles excluded
16 duplicate populations
13 no AE data
1 no DP given
1 no repeat courses of DP
2 review/commentary
2 other*
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(pooled IRR; ﬁ gure 2). This was 75% in east Africa, 
91% in west Africa, and 97% in adults in 
Thailand36 (appendix).
Monthly IPT with DP provided similar eﬃ  cacy to 
monthly SP+amodiaquine for preventing any para-
sitaemia, but inferior eﬃ  cacy compared with monthly 
SP+primaquine  (ﬁ gure 3). Monthly IPT-DP was signi-
ﬁ cantly better than daily co-trimoxazole, or monthly 
IPT-SP for the prevention of malaria infection.
Dosing of IPT-DP on a less than monthly schedule 
(every 2 months36 or 3 months35) provided signiﬁ cantly 
less protection against any parasitaemia than monthly 
dosing (ﬁ gure 3).
The considerable heterogeneity (I²>75%) among 
placebo controlled RCTs was partly explained by 
diﬀ erence in quality of the trials as established by 
the Cochrane Collaboration’s tool:25 there was no hetero-
geneity in the two RCTs classiﬁ ed as having low potential 
Country Study type Study population Comparators* Eﬃ  cacy data SAE† Deaths DOT,‡ number of 
courses
Bigira,
201431
Uganda Clinical trial-IPT Children under 
5 years including 
HIV exposed infants
DP 98
SP 98
CTX 99
No treatment 98
Monthly active detection of 
parasitaemia from 
6–24 months of age
DP 13
SP 52
CTX 29
No treatment 26
DP 0
SP 2
CTX 2
No treatment 1
First dose DOT, 
1592 courses 
administered§
Bojang,
201032
The Gambia Clinical trial-IPT Children under 
5 years
DP 336 (335, 328)
SP+AQ 336
SP+PQ 336
No treatment 286
Any malaria within 16-week 
rainy season (passive 
surveillance), active detection 
at study end
DP 4
SP+AQ 2
SP+PQ 1
No treatment 0
DP 1
SP+AQ 0
SP+PQ 0
No treatment 0
All doses DOT, 
952 courses 
administered
Cisse,
200933
Senegal Clinical trial-IPT Children under 
5 years
DP 598 (578, 539)
SP+AQ 607
SP+PQ 654
Passive detection of malaria 
during 4-month rainy 
season, active detection at 
study end
DP 2
SP+AQ 2
SP+PQ 2
DP 2
SP+AQ 2
SP+PQ 2
First dose DOT, 
1544 courses 
administered
Desai,
201537
Kenya Clinical trial-IPT Pregnant women in 
second or third 
trimester
IPT-DP 516 (516, 477)
IST-DP 515 (167, 27)
IPT-SP 515
Active detection of 
parasitaemia at each 
antenatal clinic visit during 
pregnancy
IPT-DP 37
IST-DP 82
IPT-SP 85
IPT-DP 0
IST-DP 1
IPT-SP 2
First dose DOT, 
1585 courses 
administered
Kakuru,
201538
Uganda Clinical trial-IPT Pregnant women in 
second or third 
trimester
DP monthly 100
DP x3 94
SP x3 106
Monthly assessment with 
LAMP¶
DP monthly 4
DP x3 9
SP x3 6
DP monthly 0
DP x3 0
SP x3 0
First dose DOT, 
1136 courses 
administered
Kamya,
201434
Uganda Clinical trial-IPT Children under 
5 years
DP 47
SP 46
CTX 47
No treatment 46
Monthly active detection of 
parasitaemia from age 
4–5 months until age 
24 months
DP 10
SP 23
CTX 16
No treatment 21
DP 1
SP 2
CTX 2 No 
treatment 2
No DOT, drug intake 
recorded by parents, 
561 courses 
administered§
Lwin,
201236
Thailand Clinical trial-IPT Adults DP 387
DP Q2month 381
Placebo 193
Monthly active detection of 
parasitaemia for 36 weeks
DP 1
DP Q2 month 0
Placebo 0
DP 1
DP Q2 month 0
Placebo 0
All doses DOT, 
4089 courses 
administered§
Nankabirwa, 
201435
Uganda Clinical trial-IPT School-age children 
(aged 6–14 years)
DP 244
DP quarterly 248
Placebo 248
Monthly active detection of 
parasitaemia for 12 months
DP 6
DP quarterly 5
Placebo 2
DP 0
DP quarterly 1
Placebo 0
All doses DOT, 
2648 courses 
administered
Poespoprodjo, 
201430
Indonesia Cohort 
study-treatment
Pregnant women in 
second or 
third trimester
DP 408 (408, 64) ||
SP+CQ 24
Quinine 402
No treatment 4454
No DP 10
SP+CQ 0
Quinine 18
No treatment 134
DP 0
SP+CQ 0
Quinine 0
No treatment 0
First dose DOT, 
486 courses 
administered
Wanzira, 
201420
Uganda Clinical 
trial-treatment
Children under 
5 years including 
HIV exposed infants
DP (+/- CTX) 154
(154, 147) **
AL (+/- CTX) 158
Passive detection of 
parasitaemia before age 
5 years
DP 13
DP+CTX 23
AL 39
AL+CTX 14
DP 0
DP+CTX 4
AL 1
AL+CTX 3
First dose DOT, 
2218 courses 
administered
Zongo,
20156
Burkina Faso Clinical trial-IPT Children under 
5 years
DP 750 (757) ††
SP+AQ 749 (742) ††
No treatment 250
Monthly active detection of 
parasitaemia for 4 months
DP 6
SP+AQ 3
No treatment 2
DP 4
SP+AQ 2
No treatment 1
All doses DOT, 
2063 courses 
administered
SAE=serious adverse event. DOT=directly observed therapy. IPT=intermittent preventive treatment. IST=intermittent screening and treatment. DP=dihydroartemisinin-piperaquine. SP=sulfadoxine 
pyrimethamine. CTX=co-trimoxazole. AQ=amodiaquine, PQ=piperaquine. CQ=chloroquine. AL=artemether-lumefantrine. Q2month=every other month. CHW=community health worker. LAMP=loop-mediated 
isothermal ampliﬁ cation. *Numbers in brackets represent the number who received one or more and two or more courses of DP, if reported to be diﬀ erent from the overall sample size in the DP group. †In 
addition to any other SAEs reported by the study, all hospital admissions and deaths were considered SAEs. SAEs were reported unrelated to study drugs unless otherwise noted: Bigira and colleagues reported 
19 (4·5%) grade 3–4 AEs as possibly related to study drugs, with no signiﬁ cant diﬀ erences between the intervention groups. Desai and colleagues reported one drug related SAE (an allergic reaction to DP); 
Kakuru and colleagues reported one patient who developed anaemia after both the ﬁ rst and second dose of DP, after which DP was stopped; Kamya and colleagues reported eight (5·6%) AEs possibly related to 
study drugs, with no signiﬁ cant diﬀ erences between the intervention groups; Lwin and colleagues reported that four patients withdrew due to drug related AEs (two in the DP every other month group and two 
in placebo group). ‡DOT by study staﬀ , ﬁ rst dose=only the ﬁ rst dose of each course was administered as DOT. §The total number of doses was divided by three to estimate the number of courses and rounded to 
the nearest whole number. ¶Reported prevalence over the course of pregnancy (incidence was not reported). ||Average duration between courses 4·2 months **Average duration between courses 2·2 months 
††Intention to treat included 750 in the DP group and 740 in the SP+AQ group, but due to allocation errors, 757 were given DP and 742 were given SP+AQ.
Table: Details of included studies
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for bias (I²=0%) but high heterogeneity (I²=99·6%) 
among the four RCTs classiﬁ ed as having moderate 
potential for bias (appendix). Absence of variability in 
study quality within each comparator drug subgroup 
precluded further assessment of the inﬂ uence of the risk 
of bias on the heterogeneity by comparator drug. 
Figure 2: Pooled incidence rate ratio for any parasitaemia, monthly dihydroartemisinin-piperaquine vs placebo
DP=dihydroartemisinin-piperaquine. PYAR=person-years at risk. IR=incidence rate. IRR=incidence rate ratio. Lwin and colleagues36 and Zongo and colleagues6 did not 
report PYAR, instead they reported cumulative incidence over a year. PYAR was calculated based on the incidence rate and number of events. Zongo and colleagues’6 
numbers are based on intent to treat.
Weight (%)IRR for any 
parasitaemia (95% CI)
Country
Bigira, 200431
Bojang, 201032
Kamya, 201434
Lwin, 201236
Nankabirwa, 201435
Zongo, 20156
Overall (I²=99·4%, p=0·000)
Note: weights are from random-eﬀects analysis
Uganda
The Gambia
Uganda
Thailand
Uganda
Burkina Faso
98
336
47
387
244
750
98
336
46
193
248
250
366/121·3
7/67·84
82/44·7
5/166·7
3/240·5
205/186·4
760/109·3
41/51·81
240/38·2
69/70·4
83/242·7
328/19·1
3·02
0·1
1·83
0·03
0·01
1·1
0·43 (0·41–0·46)
0·13 (0·08–0·19)
0·29 (0·26–0·33)
0·03 (0·02–0·05)
0·03 (0·01–0·08)
0·06 (0·06–0·07)
0·16 (0·06–0·26)
6·95
0·79
6·28
0·98
0·34
17·17
16·74
16·23
16·58
16·88
16·63
16·93
100·00
No treatment
No treatment
No treatment
Placebo
Placebo
No treatment
DP
Exposed Events/PYAR IR
Comparator
ExposedTherapy Events/PYAR IR
DP better DP worse
0·5 1·00·0
Figure 3: Pooled incidence rate ratio or relative risk for any parasitaemia, monthly dihydroartemisinin-piperaquine vs any other therapy
DP=dihydroartemisinin-piperaquine. PYAR=person-years at risk. IR=incidence rate. IRR=incidence rate ratio. CTX=co-trimoxazole. SP=sulfadoxine-pyrimethamine. 
SP+PQ=sulfadoxine-pyrimethamine piperaquine. SP+AQ=sulfadoxine-pyrimethamine amodiaquine. AL=artemether lumefantrine. Lwin and colleagues36 and Zongo 
and colleagues6 did not report PYAR. PYAR was calculated based on the incidence rate and number of events. Cisse and colleagues32 reported cumulative incidence. 
Kakuru37 reported detection of malaria parasites by LAMP at each visit as the prevalence of positive tests during pregnancy out of all tests. Zongo and colleagues’6 
numbers are based on intention to treat.
Weight
(%)
IRR for any 
parasitaemia (95% CI)
Country
Monthly DP vs CTX for IPT
Bigira, 201431
Kamya, 201434
Subtotal (I²=30·7%, p=0·230)
Monthly DP vs SP for IPT
Bigira, 201431
Kamya, 201434
Desai, 201537
Kakuru, 201538
Subtotal (I²=97·2%, p=0·00)
Monthly DP vs SP+PQ for IPT
Bojang, 201032
Cisse, 200933
Subtotal (I²=0·0%, p=0·854)
Monthly DP vs SP+AQ for IPT
Bojang, 201032
Cisse, 200933
Zongo, 20156
Subtotal (I²=81·5%, p=0·004)
Monthly DP vs Alternative DP for IPT
Lwin, 201236
Nankabirwa, 2014
Subtotal (I²=88·1%, p=0·004)
DP vs AL for case management
Wanzira, 201420
Subtotal (I²=·%, p=·)
Note: weights are from random-eﬀects analysis
Uganda
Uganda
Uganda
Uganda
Kenya
Uganda
The Gambia
Senegal
The Gambia
Senegal
Burkina Faso
Thailand
Uganda
Uganda
98
47
98
47
516
100
336
598
336
598
750
387
244
154
99
47
98
46
515
106
336
654
336
607
750
381
248
158
366/121·3
82/44·7
366/121·3
82/44·7
80/147·0
26/496
7/67·84
32/604
7/67·84
32/604
205/186·4
5/166·7
3/240·5
2099/408
609/116·8
116/40·6
725/107·8
182/40·4
289/150·5
206/509
4/69·6
21/618
4/68·81
36/671
147/201·4
40/190·5
81/238·1
2344/382
3·02
1·83
3·02
1·83
54·4
5·2
0·1
0·053
0·1
0·053
1·1
0·03
0·01
5·14
0·58 (0·54–0·62)
0·64 (0·56–0·74)
0·59 (0·54–0·65)
0·45 (0·42–0·48)
0·41 (0·36–0·46)
0·28 (0·25–0·32)
0·13 (0·08–0·21)
0·32 (0·19–0·44)
1·67 (0·90–3·08)
1·56 (1·23–1·98)
1·57 (1·22–1·92)
1·67 (0·90–3·08)
0·98 (0·75–1·29)
1·51 (1·36–1·68)
1·31 (0·86–1·76)
0·14 (0·09–0·23)
0·03 (0·01–0·08)
0·08 (–0·03–0·19)
0·84 (0·81–0·86)
0·84 (0·81–0·86)
5·21
2·86
6·73
4·5
192
40·5
0·06
0·034
0·06
0·054
0·73
0·21
0·34
6·14
74·51
25·49
100·00
25·60
24·77
25·41
24·22
100·00
10·58
89·42
100·00
12·66
41·36
45·98
100·00
46·37
53·63
100·00
100·00
100·00
CTX (days)
CTX (days)
SP (1 month)
SP (1 month)
SP (1 month)
SP (×3)
SP+PQ (1 month)
SP+PQ (1 month)
SP+AQ (1 month)
SP+AQ (1 month)
SP+AQ (1 month)
DP (2 months)
DP (3 months)
AL (3 days)
DP
Exposed Events/PYAR IR
Comparator
ExposedTherapy Events/PYAR IR
DP better DP worse
1·0 2·00·0 1·50·5
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Geographic stratiﬁ cation did not explain the 
heterogeneity (appendix).
Among 3960 participants, after excluding arms of studies 
where most had received no or only 1 course of DP,30,37 
133 SAEs were reported, including 23 in patients receiving 
DP+co-trimoxazole. Including all 4883 participants in DP 
groups (3935 of whom received at least two courses), 233 
SAEs were reported. An additional four SAEs were reported 
in 990 reci pients of SP+piperaquine. Among 3180 
participants receiving other treatments and 5575 receiving 
placebo, 287 and 186 SAEs were reported, respectively 
(table 1).
After correction for zero events, repeated DP exposure 
was associated with a signiﬁ cantly lower odds of SAEs 
Figure 4: Pooled odds ratios for any serious adverse event after exposure to dihydroartemisinin-piperaquine stratiﬁ ed by comparator therapy
DP=dihydroartemisinin-piperaquine. SAE=serious adverse event. CTX=co-trimoxazole. IPT=intermittent preventive treatment. IST=intermittent screening and 
treatment. SP=sulfadoxine-pyrimethamine. SP+PQ=sulfadoxine-pyrimethamine piperaquine. SP+AQ=sulfadoxine-pyrimethamine amodiaquine. SP+CQ=sul
fadoxine-pyrimethamine  chloroquine. AL=artemether-lumefantrine. Zongo and colleagues’6 numbers are based on actual drug exposures. Poespoprodjo and 
colleagues30: only 64 of 408 DP recipients received two or more courses of DP, but information of SAEs by number of courses received was not available.
Weight (%)OR (95% CI)Country Comparator
therapy
Comparator: 
SAE/exposed
DP: 
SAE/exposed
Monthly DP vs CTX for IPT
Bigira, 201431
Kamya, 201434
Subtotal  (I²=0·0%, p=0·560)
Monthy DP vs Placebo for IPT
Bigira, 201431
Bojang, 201032
Kamya, 201434
Lwin, 201236
Nankabirwa, 201438
Zongo, 20156
Subtotal  (I²=48·9%, p=0·081)
Monthly DP vs SP for IPT
Bigira, 201431
Kamya, 201434
Desai, 201537
Kakuru, 201538
Subtotal  (I²=63·4%, p=0·042)
Monthly DP vs SP+PQ for IPT
Bojang, 201032
Cisse, 200933
Subtotal  (I²=0·0%, p=0·382)
Monthly DP vs SP+AQ for IPT
Bojang, 201032
Cisse, 200933
Zongo, 2015xx
Subtotal  (I²=0·0%, p=0·841)
Monthly DP vs Alternative IPT-DP or IST-DP
Lwin, 201236
Nankabirwa, 201435
Desai, 201537
Kakuru, 201538
Subtotal  (I²=29·3%, p=0·236)
DP vs Other therapies for case management
Poespoprodjo, 201430
Poespoprodjo, 201430
Subtotal  (I²=0·0%, p=0·562)
DP vs AL for case management
Wanzira, 201420
Wanzira, 201420
Subtotal  (I²=95·2%, p=0·000)
 13/98
 10/47
 13/98
 4/336
 10/47
 1/386
 6/244
 6/757
 13/98
 10/47
 37/508
 4/100
 4/336
 2/598
 4/336
 2/598
 6/757
 1/386
 6/244
 37/508
 4/100
 10/408
 10/408
 23/26
 13/128
0·37 (0·18–0·76)
0·52 (0·21–1·32)
0·42 (0·24–0·74)
0·42 (0·20–0·88)
9·11 (0·49–169·84)
0·32 (0·13–0·80)
1·50 (0·06–37·04)
2·06 (0·51–8·33)
0·99 (0·20–4·94)
0·63 (0·40–1·00)
0·14 (0·07–0·27)
0·27 (0·11–0·67)
0·39 (0·26–0·59)
0·69 (0·19–2·54)
0·31 (0·23–0·43)
4·04 (0·45–36·30)
1·09 (0·15–7·79)
2·10 (0·52–8·46)
2·01 (0·37–11·06)
1·02 (0·14–7·23)
1·97 (0·49–7·90)
1·71 (0·67–4·36)
2·96 (0·12–72·92)
1·23 (0·37–4·07)
0·41 (0·27–0·61)
0·39 (0·12–1·32)
0·46 (0·32–0·67)
1·29 (0·07–22·69)
0·54 (0·24–1·18)
0·57 (0·27–1·21)
9·31 (2·31–37·59)
0·26 (0·13–0·51)
0·62 (0·37–1·04)
CTX (days)
CTX (days)
No treatment
No treatment
No treatment
Placebo
Placebo
No treatment
SP (1 month)
SP (1 month)
SP (1 month)
SP (x3)
SP+PQ (1 month)
SP+PQ (1 month)
SP+AQ (1 month)
SP+AQ (1 month)
SP+AQ (1 month)
DP (2 months)
DP (3 months)
IST-DP
DP (x3)
SP+CQ (3 days)
Quinine (7 days)
AL+CTX
AL (3 days)
Uganda
Uganda
Uganda
The Gambia
Uganda
Thailand
Uganda
Burkina Faso
Uganda
Uganda
Kenya
Uganda
The Gambia
Senegal
The Gambia
Senegal
Burkina Faso
Thailand
Uganda
Kenya
Uganda
Indonesia
Indonesia
Uganda
Uganda
 13/98
 10/47
 13/98
 4/336
 10/47
 1/386
 6/244
 6/757
 13/98
 10/47
 37/508
 4/100
 4/336
 2/598
 4/336
 2/598
 6/757
 1/386
 6/244
 37/508
 4/100
 10/408
 10/408
 23/26
 13/128
 66·52
 33·48
 100·00
 48·70
 1·07
 36·09
 1·43
 6·27
 6·44
 100·00
 30·56
 12·40
 53·25
 3·79
 100·00
 34·16
 65·84
 100·00
 28·39
 28·42
 43·19
 100·00
 0·56
 5·36
 84·22
 9·86
 100·00
 4·93
 95·07
 100·00
 4·02
 95·98
 100·00
DP better DP worse
1·00·05 75·00·5 2·0
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compared with placebo, co-trimoxazole, or IPT-SP 
(ﬁ gure 4). IPT-DP was also associated with fewer 
hospital admissions than IPT-SP (appendix). Repeated 
case management with DP was associated with fewer 
hospital admissions compared with AL (appendix).
None of the 11 studies reported SAEs was consistent 
with sudden cardiac death. Overall, 15 deaths were 
reported among those exposed to DP, two among those 
exposed to SP+piperaquine, 18 among those exposed to 
other comparator therapies, and four among those in 
placebo groups. No studies reported any sudden or 
unexplained deaths (ﬁ gure 5, appendix). IPTp-DP was 
not associated with an increased risk of loss to follow-up 
(which could reﬂ ect undetected or unreported sudden 
Figure 5: Pooled odds ratios for death after exposure to repeated courses of dihydroartemisinin-piperaquine stratiﬁ ed by comparator therapy
Comparisons with zero events in both groups were excluded from the analysis of the pooled OR. OR=odds ratio. DP=dihydroartemisinin-piperaquine. 
CTX=co-trimoxazole. IPT=intermittent preventive treatment. IST=intermittent screening and treatment. SP=sulfadoxine-pyrimethamine. 
SP+PQ=sulfadoxine-pyrimethamine piperaquine. SP+AQ=sulfadoxine-pyrimethamine amodiaquine. SP+CQ=sulfadoxine-pyrimethamine chloroquine. 
AL=artemether-lumefantrine. Zongo and colleagues’6 numbers are based on actual drug exposures. Poespoprodjo and colleagues: only 64 of 408 DP recipients 
received two or more courses of DP.
Weight (%)OR (95% CI)Country Comparator
therapy
Comparator
deaths
DP deaths
Monthly DP vs CTX for IPT
Bigira, 201431
Kamya, 201434
Subtotal (I2= 0·0%, p=0·647)
Monthy DP vs placebo for IPT
Bigira, 201431
Bojang, 201032
Kamya, 201434
Lwin, 201236
Zongo, 20156
Nankabirwa, 201435
Subtotal  (I2=0·0%, p=0·847)
Monthly DP vs SP for IPT
Bigira, 201431
Kamya, 201434
Desai, 201537
Kakuru, 201538
Subtotal  (I2=0·0%, p=0·652)
Monthly DP vs SP+PQ for IPT
Bojang, 201032
Cisse, 200933
Subtotal  (I2=0·0%, p=0·597)
Monthly DP vs SP+AQ for IPT
Bojang, 201032
Cisse, 200933
Zongo, 20156
Subtotal  (I2=0·0%, p=0·814)
Monthly DP vs alternative IPT-DP or IST-DP
Lwin, 201236
Nankabirwa, 201435
Desai, 201537
Kakuru, 201538
Subtotal  (I2=0·0%, p=0·553)
DP vs other therapies for case management
Poespoprodjo, 2014xx
Poespoprodjo, 2014xx
Subtotal  (NA)
DP vs AL for case management
Wanzira, 201430
Wanzira, 201430
Subtotal  (I2=0·0%, p=0·367)
2/99
2/47
1/98
0/336
2/46
0/193
1/250
0/248
2/98
2/46
0/510
0/106
0/336
2/654
0/336
2/607
2/742
0/381
1/248
1/510
0/94
0/24
0/402
3/31
1/127
0·20 (0·01–4·18)
0·49 (0·04–5·59)
0·33 (0·05–2·11)
0·33 (0·01–8·20)
3·01 (0·12–74·13)
0·48 (0·04–5·46)
1·50 (0·06–37·04)
1·32 (0·15–11·89)
(Excluded)
0·96 (0·31–2·98)
0·20 (0·01–4·13)
0·48 (0·04–5·46)
(Excluded)
(Excluded)
0·32 (0·05–2·08)
3·01 (0·12–74·13)
1·09 (0·15–7·79)
1·49 (0·29–7·61)
3·01 (0·12–74·13)
1·02 (0·14–7·23)
1·97 (0·36–10·76)
1·66 (0·52–5·36)
2·96 (0·12–72·92)
0·34 (0·01–8·32)
0·33 (0·01–8·22)
(Excluded)
0·71 (0·14–3·63)
(Excluded)
(Excluded)
NA
1·70 (0·34–8·39)
0·33 (0·01–8·13)
1·16 (0·30–4·54)
CTX (day)
CTX (day)
No treatment
No treatment
No treatment
Placebo
No treatment
Placebo
SP (1 month)
SP (1 month)
SP (1 month)
SP (x3)
SP+PQ (1 month)
SP+PQ (1 month)
SP+AQ (1 month)
SP+AQ (1 month)
SP+AQ (1 month)
DP (2 months)
DP (3 months)
IST-DP
DP (x3)
SP+CQ (3 days)
Quinine (7 days)
AL+CTX
AL (3 days)
Uganda
Uganda
Uganda
The Gambia
Uganda
Thailand
Burkina Faso
Uganda
Uganda
Uganda
Kenya
Uganda
The Gambia
Senegal
The Gambia
Senegal
Burkina Faso
Thailand
Uganda
Kenya
Uganda
Indonesia
Indonesia
Uganda
Uganda
0/98
1/47
0/98
1/336
1/47
1/387
4/757
0/244
0/98
1/47
0/508
0/100
1/336
2/598
1/336
2/598
4/757
1/387
0/244
0/508
0/100
0/408
0/408
4/26
0/128
 55·84
 44·16
 100·00
 24·35
 8·12
 32·28
 10·84
 24·40
 0·00
 100·00
 55·70
 44·30
 0·00
 0·00
 100·00
 20·72
 79·28
 100·00
 11·10
 44·11
 44·80
 100·00
 14·41
 42·64
 42·95
 0·00
 100·00
 0·00
 0·00
 0·00
 60·69
 39·31
 100·00
DP better DP worse
1·00·05 75·00·5 2·0
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death) compared with co-trimoxazole, SP, SP + piper-
aquine, or SP+amodiaquine, but was associated with a 
47% higher risk of loss to follow-up compared with 
placebo (appendix).
The eﬀ ect of DP on cardiac repolarisation was assessed 
in 19 HIV-unexposed31 and seven HIV-exposed children 
(Dorsey, unpublished) and 30 pregnant women.38 In the 
26 children, 183 ECGs were conducted at baseline and 
follow-up (4–6 h after the third dose of DP with each 
monthly course); all of the baseline and follow-up ECGs 
had a QTc less than 450 ms with a mean QTc of 396 ms 
(SD 31·3, range 278–444). There were no diﬀ erences in 
the mean QTc intervals measured after the third dose for 
children who had been prescribed three to ﬁ ve previous 
courses of DP (mean QTc 405 ms, SD 26), six to 
ten previous courses of DP (388 ms, 33), or 11–18 previous 
courses of DP (396 ms, 33). None of the 30 pregnant 
women who underwent ECG measurements at 28 weeks’ 
gestational age pre-dosing and post-dosing had QTc 
intervals greater than 450 ms.38 The median increase in 
QTc from baseline to 4–6 hours after the third dose was 
30 ms (range –30 to 50) and 20 ms (–10 to 50) in women 
randomised to receive monthly DP (n=13) and 3 doses of 
DP (n=17), respectively, compared with 5 ms (–40 to 60) in 
women who received three doses of SP (n=12, p=0·57 and 
0·28 for monthly and three dose DP compared with 
three dose SP).
IPT-DP was associated with similar cumulative risk of 
any vomiting compared with placebo, SP, and 
SP+amodiaquine, and with a lower risk compared with 
SP+primaquine (appendix). In the single treatment 
study with tolerability data, DP was associated with a 
lower risk of vomiting compared with AL (RR 0·52, 95% 
CI 0·45–0·61).20
In children under 5 years of age, both IPT-DP and 
IPT-SP were associated with more vomiting during the 
ﬁ rst course than subsequent monthly courses (DP around 
4% vs <2%; SP around 3·5% vs <2%).6 No vomiting was 
reported among school-aged (6–14 years) children 
receiving monthly IPT-DP after any of the three courses.35 
Treatment of clinical malaria with DP was not associated 
with more vomiting than AL for the ﬁ rst and second 
courses, and for the third course, participants given DP 
vomited less than those given AL (2·8% vs 7·8% p=0·08).20
IPT-DP was not associated with an increased risk of 
diarrhoea compared with placebo, SP+amodiaquine, 
SP+primaquine, or IPT-SP in six studies (appendix).
Only four studies provided data on rash or allergic 
reactions, and no study reported any SAEs due to allergic 
reactions. IPT-DP was not associated with an increased 
risk of rash compared with placebo, SP+primaquine or 
SP+amodiaquine (appendix).
Discussion
This meta-analysis suggests that DP is as safe as other 
combinations assessed for IPT or the repeat treatment of 
clinical malaria, and that it was well tolerated. DP 
provided superior protection against malaria and resulted 
in fewer hospital admissions than comparators. In 
comparison with dosing every 2 or 3 months, monthly 
administration of DP provided much better protection 
from malaria, without increasing the risk of adverse 
events or adversely aﬀ ecting tolerability.35–38
DP, like some other antimalarials, has been associated 
with dose dependent risk for QTc prolongation. 
A previous review assessing the risk of QTc prolongation 
following a single course of treatment found no 
diﬀ erence in the risk for prolonged QTc between DP and 
AL, but DP was associated with more frequent pro-
longation of the QTc interval compared with meﬂ oquine-
artesunate.39 No cardiac arrhythmias or sudden death 
were reported for any of the drugs, although it is possible 
that sudden death due to a cardiac arrhythmia could have 
been incorrectly attributed to other causes. Similarly, in 
our meta-analysis, no cardiac events were reported 
among 3935 recipients of repeat courses of DP involving 
18 297 courses of DP ranging from two to 18 courses per 
individual. As only three studies in diﬀ erent populations 
assessed the eﬀ ect of DP on the ECG, it was not possible 
to do a meta-analysis to assess the risk of repeated 
courses of DP on the ECG; however, no signiﬁ cant QT 
prolongation was reported with repeat dosing in the 
individual studies. Furthermore, the risk of death was 
not signiﬁ cantly increased following receipt of repeat 
courses of DP, suggesting no signiﬁ cant increased risk 
of sudden cardiac death, although the rare nature of this 
event makes it diﬃ  cult to rule out. It should be noted, 
however, that although DP was not associated with 
increased loss to follow-up compared with comparators, 
there was more loss to follow-up among participants in 
the DP group in the studies comparing DP against 
placebo.  This was driven primarily by the high loss to 
follow-up in Lwin and colleagues,36 which was unrelated 
to the intervention since only four withdrew due to 
adverse events: two from the IPT group and two from the 
placebo group. The rest were lost due to other reasons.
The clinical relevance of the dose dependent risk for 
QTc prolongation with DP is not clear, since the pro-
arrhythmic potential of piperaquine in vitro appears 
lower than chloroquine and similar to AL.23 One 
post-marketing study, comparing a compressed 2-day 
regimen of DP with placebo, has reported clinically 
signiﬁ cant QT prolongation among participants exposed 
to DP.19 Given the potential for dose accumulation with 
monthly dosing,36 it was reassuring to ﬁ nd that the 
studies in children did not ﬁ nd evidence that repeat 
monthly courses were associated with greater degrees of 
QT prolongation than the ﬁ rst course, even among 
children that had received ten or more monthly courses31 
(Dorsey, unpublished data).
It is possible that the absence of additional QTc 
prolongation with repeat courses reﬂ ects the ﬁ nding that 
QTc interval returns to normal within approximately 
12–48 h following the last dose after each course. 
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Nevertheless, some increase in QTc prolongation with 
increasing number of courses could not be excluded in 
pregnant women,38 and the strength of the evidence to 
date is limited because ECGs were only done in three 
studies involving 56 participants receiving monthly 
courses, thus more studies are needed. Advances in 
mobile adapted technology, such as Smartheart or 
AliveCor, might allow for improved monitoring of patients 
in remote and resource poor settings in the future.
Our search did not ﬁ nd any studies where repeat 
courses of DP were provided as part of malaria 
elimination campaigns that often involve multiple 
rounds of mass drug administration within a single year. 
However, our ﬁ ndings with DP as IPT are likely to be 
generalisable to mass drug administration since both 
strategies involve asymptomatic carriers of malaria 
parasites and individuals without malaria parasites at the 
time of drug administration.
The few people exposed to multiple courses of DP to 
date precludes our ability to detect an increased risk of an 
arrhythmia such as torsadogenic event that occur in 
about one in 10 000 exposures to QT prolonging drugs; 
our overall sample size can only exclude (95% CI) such 
events in one in 6099 exposures.  The fact that diﬀ erent 
patient populations were grouped is a potential weakness, 
as the QTc (and risk for cardiotoxicity) is aﬀ ected by 
age, sex, and pregnancy status, and achieved drug 
concentrations might also vary by patient population and 
gestational age; however, the paucity of data precluded 
reviewing the groups individually.  The included studies 
involving young children were conducted before WHO’s 
dose increase for DP in children aged 1–4 years,4 and 
continued collection of safety data with the new dose is 
needed. One of the treatment studies included many 
participants who only received a single course of DP. 
However, no details were provided in the source study 
that allowed a breakdown of SAEs by number of courses. 
Finally, it is possible that restricting to English language 
excluded relevant studies published in other languages.
In this meta-analysis of nearly 4000 patients exposed to 
repeated courses of DP, IPT-DP was highly eﬀ ective for 
the prevention of malaria and reduced all-cause hospital 
admission compared with other drugs, particularly when 
provided as monthly courses. Overall, DP was well 
tolerated, with no evidence of increased frequency of 
mild or serious adverse events with repeated dosing. The 
data do not suggest that the known risk of QT 
prolongation increases with repeated monthly courses, 
or an increased risk of cardiac events or death following 
repeated dosing. DP is a valuable potential candidate for 
use as IPT and ongoing monitoring for cardiac events is 
needed to provide further reassurance of its safety with 
repeat doses.
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